Holtzman Douglas
- SEC CIK
- 0001874371
No open-market purchases or sales filed in the past year.
Current role at each company
- ICVX Icosavax, Inc.Chief Scientific Officeras of Jul 3, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Holtzman Douglas as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 3, 2023 (view filing) | Jul 3 | Same day | Holtzman DouglasChief Scientific Officer | SSale | −16.4K | $8.85 | −$144.7K | −5.3%290.1K after | 2 lots10b5-1 |
| Apr 5, 2023 (view filing) | Apr 3 | 2 days | Holtzman DouglasChief Scientific Officer | SSale | −20.4K | $6.09 | −$124.4K | −6.6%290.1K after | 2 lots10b5-1 |
| Feb 15, 2023 (view filing) | Feb 13-14 | 2 days | Holtzman DouglasChief Scientific Officer | SSale | −4.87K | $10.33 | −$50.3K | −1.7%290.1K after | 2 lots |
| Dec 16, 2022 (view filing) | Dec 15 | 1 day | Holtzman DouglasChief Scientific Officer | SSale | −19.6K | $11.14 | −$218.9K | −87.6%2.79K after | |
| Aug 2, 2022 (view filing) | Jul 29-Aug 2 | 4 days | Holtzman DouglasChief Scientific Officer | SSale | −10.4K | $6.67 | −$69.2K | −3.4%293.3K after | 3 lots |